{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vehicle+of+loteprednol+etabonate", "query": { "intervention": "Vehicle of loteprednol etabonate" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 19, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vehicle+of+loteprednol+etabonate&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-04T05:01:18.394Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02813265", "title": "Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dry Eye Syndromes", "Keratoconjunctivitis Sicca" ], "interventions": [ { "name": "KPI-121 0.25% Ophthalmic Suspension", "type": "DRUG" }, { "name": "Vehicle of KPI-121 0.25% Ophthalmic Suspension", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kala Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 918, "start_date": "2016-06", "completion_date": "2017-10", "has_results": true, "last_update_posted_date": "2021-02-03", "last_synced_at": "2026-10-04T05:01:18.394Z", "location_count": 60, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 53 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Artesia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02813265" }, { "nct_id": "NCT02819284", "title": "Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dry Eye Syndromes", "Keratoconjunctivitis Sicca" ], "interventions": [ { "name": "KPI-121 0.25% Ophthalmic Suspension", "type": "DRUG" }, { "name": "Vehicle of KPI-121 0.25% Ophthalmic Suspension", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kala Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 909, "start_date": "2016-06", "completion_date": "2017-09", "has_results": true, "last_update_posted_date": "2021-01-05", "last_synced_at": "2026-10-04T05:01:18.394Z", "location_count": 62, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Jonesboro, Arkansas + 54 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Artesia", "state": "California" }, { "city": "Azusa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02819284" }, { "nct_id": "NCT00699153", "title": "Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ocular Inflammation" ], "interventions": [ { "name": "Loteprednol Etabonate", "type": "DRUG" }, { "name": "Vehicle of Ophthalmic Loteprednol Etabonate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bausch & Lomb Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2008-06", "completion_date": "2009-06", "has_results": true, "last_update_posted_date": "2015-03-24", "last_synced_at": "2026-10-04T05:01:18.394Z", "location_count": 1, "location_summary": "High Point, North Carolina", "locations": [ { "city": "High Point", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00699153" }, { "nct_id": "NCT01060072", "title": "Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Inflammation", "Pain" ], "interventions": [ { "name": "Loteprednol etabonate", "type": "DRUG" }, { "name": "Vehicle of Loteprednol Etabonate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bausch & Lomb Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 407, "start_date": "2010-02", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2012-01-13", "last_synced_at": "2026-10-04T05:01:18.394Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01060072" }, { "nct_id": "NCT00420628", "title": "Pediatric Zylet Safety and Efficacy Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chalazion", "Hordeolum" ], "interventions": [ { "name": "loteprednol etabonate/tobramycin opthalmic suspension", "type": "DRUG" }, { "name": "vehicle", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bausch & Lomb Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "6 Years", "sex": "ALL", "summary": "Up to 6 Years" }, "enrollment_count": 108, "start_date": "2006-11", "completion_date": "2009-06", "has_results": true, "last_update_posted_date": "2011-10-07", "last_synced_at": "2026-10-04T05:01:18.394Z", "location_count": 1, "location_summary": "Erie, Pennsylvania", "locations": [ { "city": "Erie", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00420628" }, { "nct_id": "NCT00645671", "title": "Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ocular Inflammation" ], "interventions": [ { "name": "0.5% Loteprednol Etabonate Ophthalmic Ointment", "type": "DRUG" }, { "name": "Vehicle of Loteprednol Etabonate Ophthalmic Ointment", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bausch & Lomb Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2008-03", "completion_date": "2009-03", "has_results": true, "last_update_posted_date": "2015-03-24", "last_synced_at": "2026-10-04T05:01:18.394Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00645671" }, { "nct_id": "NCT01107405", "title": "Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Allergic Conjunctivitis" ], "interventions": [ { "name": "Loteprednol etabonate base (QD)", "type": "DRUG" }, { "name": "Loteprednol etabonate base (BID)", "type": "DRUG" }, { "name": "Loteprednol etabonate base (QID)", "type": "DRUG" }, { "name": "Loteprednol etabonate suspension", "type": "DRUG" }, { "name": "Vehicle of loteprednol etabonate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bausch & Lomb Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": null, "sex": "ALL", "summary": "10 Years and older" }, "enrollment_count": 101, "start_date": "2010-04", "completion_date": "2010-08", "has_results": true, "last_update_posted_date": "2012-03-21", "last_synced_at": "2026-10-04T05:01:18.394Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01107405" }, { "nct_id": "NCT05322148", "title": "Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dry Eye" ], "interventions": [ { "name": "Klarity CL, Cylcosporine 0.1%/Loteprednol Etabonate 0.2% Preservative Free", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Research Insight LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2022-06-03", "completion_date": "2022-11-21", "has_results": false, "last_update_posted_date": "2023-01-04", "last_synced_at": "2026-10-04T05:01:18.394Z", "location_count": 3, "location_summary": "Hemet, California • Laguna Hills, California • Brecksville, Ohio", "locations": [ { "city": "Hemet", "state": "California" }, { "city": "Laguna Hills", "state": "California" }, { "city": "Brecksville", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05322148" }, { "nct_id": "NCT02163824", "title": "Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ocular Infections, Irritations and Inflammations" ], "interventions": [ { "name": "KPI-121 0.25%", "type": "DRUG" }, { "name": "KPI-121 1.0%", "type": "DRUG" }, { "name": "Vehicle of KPI-121 0.25%", "type": "DRUG" }, { "name": "Vehicle of KPI-121 1.0%", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kala Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 380, "start_date": "2014-05", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2021-01-29", "last_synced_at": "2026-10-04T05:01:18.394Z", "location_count": 23, "location_summary": "Artesia, California • Mission Hills, California • Rancho Cordova, California + 17 more", "locations": [ { "city": "Artesia", "state": "California" }, { "city": "Mission Hills", "state": "California" }, { "city": "Rancho Cordova", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Morrow", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02163824" }, { "nct_id": "NCT01996839", "title": "Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Inflammation", "Pain", "Cataract" ], "interventions": [ { "name": "Loteprednol Etabonate Gel (BID)", "type": "DRUG" }, { "name": "Loteprednol Etabonate Gel (TID)", "type": "DRUG" }, { "name": "Vehicle (BID)", "type": "DRUG" }, { "name": "Vehicle (TID)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bausch & Lomb Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 514, "start_date": "2013-12", "completion_date": "2014-07", "has_results": true, "last_update_posted_date": "2020-09-25", "last_synced_at": "2026-10-04T05:01:18.394Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01996839" } ] }